Symbiotec Pharmalab Ltd Growth Catalysts - SOIC x StockScans Report
as of Nov 2026
- DCV injectables US deal - Knovea signed an exclusive long-term agreement on 30 Sep 2026 with a leading global pharma company for two dual-chamber vial injectables addressing a \~$300 mn US market; the first ANDA was filed in September 2026 with priority review and a July goal date. Milestone income of ₹53 cr was booked in Q2 FY27 with similar amounts expected yearly, and supply revenues start next fiscal year once approval and FDA inspection land in late calendar 2027.
- European alternate protein CDMO - A 10-year take-or-pay agreement signed 6 Nov 2026 reserves dedicated Ujjain fermentation capacity for a European alternative-protein maker backed by two MNCs, with Phase 0 production starting this fiscal year from the existing 100 KL. Phase 1 toll fees alone run into a few tens of millions of dollars and should sit in the P&L by FY28-29, within a \~₹1,000 cr phased project partly funded by the customer.
- US alternate protein contract - A 10-year take-or-pay contract with a US alternate-protein company is in place, with commercial batches expected in Q1 FY28 and the first product launch around April/May 2027. Management expects the customer to discuss multiples of the committed capacity once the product ships, with contracted fees escalating with inflation each year.
- Insulin and GLP-1 biologics - A 5-year take-or-pay contract for insulin drug substance is signed, with commissioning and validation batches expected in Q4 FY27 and sales from mid FY28 to an Indian partner, on a little over ₹100 cr of capex. Half the dedicated 14 KL fermentation capacity is reserved for GLP-1s and insulin analogs like Glargine and Aspart, where a manufacturing and supply agreement is already in place and validation batches are underway.
- Steroid API core growth - Q2 FY27 API revenue grew 16% YoY to ₹227 cr at 60%+ gross margins, and management guides to high single-digit (sometimes low double-digit) growth with visibility for several years. With utilization at only 70-80% of the ₹650 cr API asset base and 44 US DMFs filed, volume growth needs little new capital.
- Ujjain fermentation platform build-out - The 750 KL Phase 1 expansion at the now 72-acre Ujjain site starts construction in Q3 FY27 with a 12-15 month build, alongside advanced-stage discussions with around 4 potential customers each needing around a million litres. First small CDMO revenues arrive in Q4 FY27, with a significant chunk of CDMO revenue expected in FY28 under take-or-pay terms.
- Vegan Vitamin D3 launch - The vegan D3 plant should be finished and qualified by end of this fiscal year, with nutraceutical and veterinary sales starting early next fiscal year. The product currently sells at 3-4 times the price of animal-derived D3, and Symbiotec's process lets it compete even at animal-D3 price points.